TY - JOUR
T1 - Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan
AU - Infectious Diseases Society of Taiwan
AU - Medical Foundation in Memory of Dr. Deh-Lin Cheng
AU - Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education
AU - CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines
AU - The 5th Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group
AU - Wu, Kuan Sheng
AU - Syue, Ling Shan
AU - Cheng, Aristine
AU - Yen, Ting Yu
AU - Chen, Hsien Meng
AU - Chiu, Yu Hsin
AU - Hsu, Yu Lung
AU - Chiu, Chun Hsiang
AU - Su, Ting Yi
AU - Tsai, Wan Lin
AU - Chen, Wei Yu
AU - Huang, Chung Hao
AU - Hung, Huei Min
AU - Huang, Ling Ju
AU - Kuo, Hong Jie
AU - Lin, Pei Chin
AU - Yang, Ching Hsiang
AU - Hong, Pi Lien
AU - Lee, Susan Shin Jung
AU - Chen, Yao Shen
AU - Liu, Yung Ching
AU - Huang, Li Ming
N1 - Publisher Copyright:
© 2020
PY - 2020/4
Y1 - 2020/4
N2 - Clostridioides difficile infection (CDI) is a major enteric disease associated with antibiotic use and a leading cause of hospital-acquired infections worldwide. This is the first guideline for treatment of CDI in Taiwan, aiming to optimize medical care for patients with CDI. The target audience of this document includes all healthcare personnel who are involved in the medical care of patients with CDI. The 2018 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group was formed, comprising of infectious disease specialists from 13 medical centers in Taiwan, to review the evidence and draft recommendations using the grading of recommendations assessment, development, and evaluation (GRADE) methodology. A nationwide expert panel reviewed the recommendations during a consensus meeting in March 2019. The recommendation is endorsed by the Infectious Diseases Society of Taiwan (IDST). This guideline describes the epidemiology and risk factors of CDI, and provides recommendations for treatment of CDI in both adults and children. Recommendations for treatment of the first episode of CDI, first recurrence, second and subsequent recurrences of CDI, severe CDI, fulminant CDI, and pediatric CDI are provided.
AB - Clostridioides difficile infection (CDI) is a major enteric disease associated with antibiotic use and a leading cause of hospital-acquired infections worldwide. This is the first guideline for treatment of CDI in Taiwan, aiming to optimize medical care for patients with CDI. The target audience of this document includes all healthcare personnel who are involved in the medical care of patients with CDI. The 2018 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group was formed, comprising of infectious disease specialists from 13 medical centers in Taiwan, to review the evidence and draft recommendations using the grading of recommendations assessment, development, and evaluation (GRADE) methodology. A nationwide expert panel reviewed the recommendations during a consensus meeting in March 2019. The recommendation is endorsed by the Infectious Diseases Society of Taiwan (IDST). This guideline describes the epidemiology and risk factors of CDI, and provides recommendations for treatment of CDI in both adults and children. Recommendations for treatment of the first episode of CDI, first recurrence, second and subsequent recurrences of CDI, severe CDI, fulminant CDI, and pediatric CDI are provided.
UR - http://www.scopus.com/inward/record.url?scp=85081235315&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081235315&partnerID=8YFLogxK
U2 - 10.1016/j.jmii.2020.02.002
DO - 10.1016/j.jmii.2020.02.002
M3 - Review article
C2 - 32169531
AN - SCOPUS:85081235315
SN - 1684-1182
VL - 53
SP - 191
EP - 208
JO - Journal of Microbiology, Immunology and Infection
JF - Journal of Microbiology, Immunology and Infection
IS - 2
ER -